Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis

[1]  H. Hartung,et al.  Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats , 1995, Neuroscience Letters.

[2]  H. Lassmann,et al.  Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. , 1994, Journal of immunology.

[3]  A. Engel,et al.  Myasthenia gravis , 1993, Neurology.

[4]  V. Vetvicka,et al.  Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle. , 1993, Journal of immunology.

[5]  C. Valeri,et al.  Blockade of Complement Activation Prevents Local and Pulmonary Albumin Leak After Lower Torso Ischemia—Reperfusion , 1992, Annals of surgery.

[6]  T. Lindsay,et al.  Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. , 1992, Journal of immunology.

[7]  A. Kokla,et al.  Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor , 1992, European journal of immunology.

[8]  S. Fuchs,et al.  Acetylcholine receptor gene expression in experimental autoimmune myasthenia gravis , 1990, FEBS letters.

[9]  G. R. Carson,et al.  Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. , 1990, Science.

[10]  G. Biesecker,et al.  Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. , 1989, Journal of immunology.

[11]  P. Christadoss.  C5 gene influences the development of murine myasthenia gravis. , 1988, Journal of immunology.

[12]  A. Pestronk,et al.  Humoral Pathogenesis of Myasthenia Grayis a , 1987, Annals of the New York Academy of Sciences.

[13]  A. Engel,et al.  The Membrane Attack Complex of Complement at the Endplate in Myasthenia Gravis a , 1987, Annals of the New York Academy of Sciences.

[14]  S. Komoly,et al.  Myasthenia gravis: demonstration of membrane attack complex in muscle end-plates. , 1986, Clinical neuropathology.

[15]  A. Vincent,et al.  Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[16]  A. Vincent,et al.  Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. II. Receptor synthesis. , 1983, Journal of neurology, neurosurgery, and psychiatry.

[17]  V. Lennon,et al.  MONOCLONAL AUTOANTIBODIES TO ACETYLCHOLINE RECEPTORS: EVIDENCE FOR A DOMINANT IDIORPE AND REQUIREMENT OF COMPLEMENT FOR PATHOGENICITY * , 1981, Annals of the New York Academy of Sciences.

[18]  N. Reddy.  Current Topics in Nerve and Muscle Research , 1980 .

[19]  A. Engel,et al.  Ultrastructural Localization of the Terminal and Lytic Ninth Complement Component (C9) at the Motor End‐plate in Myasthenia Gravis , 1979, Journal of neuropathology and experimental neurology.

[20]  R. Ulevitch,et al.  Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis , 1978, The Journal of experimental medicine.

[21]  A. Engel,et al.  ULTRASTRUCTURAL LOCALIZATION OF IMMUNE COMPLEXES (IgG and C3) AT THE END‐PLATE IN EXPERIMENTAL AUTOMMUNE MYASTHENIA GRAVIS , 1977, Journal of neuropathology and experimental neurology.

[22]  J. Lindstrom,et al.  Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis , 1976, The Journal of experimental medicine.

[23]  K. Whaley,et al.  Methods in complement for clinical immunologists , 1985 .